Americas Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs, and Others), By Route of Administration (Oral, Parenteral, Rectal), By disease type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other), By end user (Hospital Pharmacies, Retail Pharmacies and Other) - Forecast till 2032

 Americas Gastrointestinal Drugs Market Overview 

Americas Gastrointestinal Drugs Market Size was valued at USD 11.20 Billion in 2023. The Global Americas Gastrointestinal Drugs industry is projected to grow from USD 12.34 Billion in 2024 to USD 16.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.20% during the forecast period (2024 - 2032).

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, oesophagus, liver, gallbladder and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation and many more. According to a report by the World Gastroenterology Organization, 35-40% of world’s total population is suffering from acute or chronic GI complication. Increasing patient having GI diseases and disorders, due to change in dietary pattern are the major factor for increasing the Americas GI drug market. The exact cause for inflammatory bowel disease and Irritable bowel syndrome are still unknown due to which permanent cure for this disease is not available which may slow down the market growth.

Study Objectives Americas Gastrointestinal Drugs Market Research Report

• To provide thorough understanding of various segment and sub segments of the gastrointestinal drugs market.


• To provide detail analysis of the various regulatory rules on the growth of market.


• To provide the detail overview of parent market.


• To provide the detail information about drivers and restraints of the market.


• To provide competitive landscape and key players in the market.


• To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.


• To provide detail trends and opportunities for the market.


• To provide historical and forecast revenue of the market segments and sub-segments with respect to geography and their sub regions- North America and South America


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Americas gastrointestinal drugs Market. 

Segmentation

The Segmentation for Americas gastrointestinal drug market is done on the basis of drug category, route of administration, disease type, and by end users. On the basis of the drug category it comprises of Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others. Further the Acid Neutralizers are sub-segmented into Antacid, H2 antagonists, Proton Pump Inhibitors and others. On the basis of route of administration the segments includes oral, parental and rectal. On the basis of disease type it includes gastroesophaeal reflux diseases, inflammatory bowel diseases and others. The inflammatory diseases are further segmented into two types Crohn’s diseases and ulcerative disease. The Ulcerative diseases are further sub segmented into ulcerative protitis, proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive colitis. The end user segment includes hospital pharmacies, retail pharmacies and others.

Regional Analysis On regional basis America gastrointestinal drug market is segmented into two main region- North America, and South America. North America has the highest market for the gastrointestinal drug market. Increasing Geriatric Population is the major driving factor for the market of GI drugs in North America. While the major cause of the gastrointestinal diseases is stress full life and eating habit.

Players for Americas Gastrointestinal Drugs market

The players in global and local gastrointestinal drug market are AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US)

The report for Americas Gastrointestinal Drugs Market Research Report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

 Intended Audience

• Gastrointestinal Drug Manufacturers.


• Pharmaceutical Industry.


• Biotechnology Companies


• Research and Development (R&D) Companies